The ¥150 billion deal, if consummated, would be part of Abbott’s move to shed assets and consolidate pending the close of its $25 billion merger with St. Jude Medical (NYSE:STJ), according to Japan’s Nikkei business journal. Earlier this month, Abbott announced plans to deal its medical optics business to Johnson & Johnson (NYSE:JNJ) for $4.3 billion.
Terumo is interested in other, unspecified assets owned by Abbott, according to the report.
For its part, Terumo is expanding its footprint in medical devices. The Japanese company put up to $380 million on the table in July for Sequent Medical and its Web aneurysm embolization device. Terumo paid $2.62 billion for CaridianBCT in 2011.